Brexpiprazole: A new treatment option for schizophrenia

Innovations in Clinical Neuroscience

Volumn 13, Issue 7-8, 2016, Pages 26-29

  Scarff, Jonathan R ^a  

^a Veterans Affairs Outpatient Clinic   (United States)

Author keywords

Antipsychotic; Brexpiprazole; Schizophrenia

Indexed keywords

BREXPIPRAZOLE; CREATINE KINASE; CYTOCHROME P450 2D6 INHIBITOR; GLUCOSE; LIPID; PROLACTIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; TRIACYLGLYCEROL;

AKATHISIA; CLINICAL GLOBAL IMPRESSION SCALE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NONHUMAN; PARTIAL AGONISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; VOLUME OF DISTRIBUTION; WEIGHT GAIN;

EID: 84988947518     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30: 67–76.
2. American Psychiatric Association. Schizophrenia spectrum and other psychotic disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Press Inc.; 2013: 87–122.
3. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry. 2007;68 Suppl 4: 4–7.
4. Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1): 169–179.
5. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in-vitro and invivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3): 589–604.
6. Rexulti (brexpiprazole) [package insert]. Tokyo, Japan: Otsuka Pharmaceuticals Inc.; 2015.
7. Oosterhof CA, El Mansari M, Blier P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in-vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014;351(3): 585–595.
8. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychoticlike and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3): 605–614.
9. Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpineinduced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015;25(3): 356–364.
10. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) rating criteria. Multi-Health Systems, North Tonawanda, NY. 1999.
11. Guy W. ECDEU Assessment Manual for Psychopharmacology (revised). Rockville, MD: National Institute of Mental Health, US Dept of Health, Education, and Welfare; pp 193–198. Publication (ADM) 76-338.
12. Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4): 323–329.
13. McQuade R, Hobart M, Forbes RA, et al. A Phase II trial assessing the efficacy and safety of OPC-34712 in the acute treatment of adult schizophrenia (Study 331-07-203). Poster presented at the 24th Annual US Psychiatric and Mental Health Congress; November 7-10, 2011; Las Vegas, NV.
14. Citrome L, Ota A, Nagamizu K, Perry P, et al. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study. Biol Psychiatry. 2015;77(9 Supp 1): 203S.
15. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, doubleblind, controlled Phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1-3): 127–135.
16. Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebocontrolled trial. Am J Psychiatry. 2015 1;172(9): 870–880.
17. Hobart M, Ouyang J, Forbes A, et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatments in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Poster presented at the American Society of Clinical Psychopharmacology Annual Meeting; June 22–25, 2015; Miami, FL.
18. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic—what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed ? Int J Clin Pract. 2015;69(9): 978–997.